Edwards Lifesciences is increasing its 2026 sales growth guidance to between 10% and 11% – from 9% to 11% previously – after achieving revenues of $1.74bn in Q2.
Edwards Q2 revenue performance reflects a 13.6% year-over-year (YoY) uplift, with its transcatheter aortic valve replacement (TAVR) segment, which drove the lion’s share of its Q2 profits at $1.26bn, growing 11.3% YoY.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Releasing its financials after markets closed on 23 July, Edwards shares on the New York Stock Exchange (NYSE) were up by 5.75% at $88.64 in premarket trading, versus a prior close of $83.82 (correct at 08.02am ET). Edwards has a market cap of $42.86bn.
On a global basis, Edwards highlighted that its SAPIEN TAVR product range’s procedural growth benefitted from “sustained clinical momentum” and the evidence supporting proactive disease management of severe aortic stenosis (AS).
In May 2025, the company shared data from a real-world study of more than 24,000 patients with severe AS, demonstrating that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients’ treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point.
Edwards’ EARLY TAVR trial (NCT03042104) supported its SAPIEN 3 device in securing an indication expansion for AS from the US Food and Drug Administration (FDA) in May 2025, making it the first TAVR system approved for use in AS patients.
Elsewhere across the business, transcatheter mitral and tricuspid therapies (TMTT) contributed $195.9m to Edwards’ Q2 revenues, indicative of a 47.3% uplift YoY. Meanwhile, surgical grew 6.5% YoY to $284m.
Edwards now expects its 2026 revenues to fall in the $6.6bn to $6.9bn range. Despite this growth, Edwards is retaining its previously outlined earnings for 2026 within the $2.95 to $3.05 per share range.
Edwards CEO, Bernard Zovighian, commented: “As Edwards continues to invest in new structural heart therapies and expand adoption globally, our results increasingly reflect the strength of our comprehensive portfolio and agile execution, with growth supported by therapies across TAVR, mitral, tricuspid and surgical, as well as meaningful contributions from each of the regions.
“Today, our company profile has evolved to include multiple strategic platforms across multiple regions that will support durable growth, which gives us confidence in our target of approximately 10% total company sales growth, on average, over the longer term.”
